e.l.f. Beauty stock plummets 20% as revenue and guidance fall short of expectations
Investing.com - BMO Capital raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $725.00 from $640.00 on Monday, while maintaining an Outperform rating on the stock. This aligns with broader analyst sentiment, as InvestingPro data shows 13 analysts have recently revised their earnings expectations upward, with price targets ranging from $595 to $910.
The firm cited "much needed relief" from Dupixent strength coupled with positive developments for Eylea HD PFS and upcoming label expansions as key factors behind the increased target. The biotech company, with a market capitalization of approximately $66.15 billion, has seen an impressive 11.36% price return over the past week.
BMO expressed encouragement regarding commentary about Eylea HD PFS filing and approval from a new facility in 2026, with RVO/Q4W dosing expected next month, potentially signaling an end to manufacturing issues that have affected the Eylea HD franchise since 2023.
The research firm noted continued outperformance of Dupixent, which has increased their confidence in the product’s long-term growth potential as COPD sales continue to inflect higher.
Regeneron has faced manufacturing challenges with Eylea HD, including Complete Response Letters (CRLs) from regulators, making the progress toward resolving these issues particularly significant for the company’s outlook.
In other recent news, Regeneron Pharmaceuticals reported strong third-quarter 2025 earnings, with earnings per share reaching $11.83, significantly above the forecasted $9.64. The company’s revenue also exceeded expectations, totaling $3.8 billion compared to the anticipated $3.59 billion. Following these results, several financial firms adjusted their outlooks on Regeneron. Guggenheim raised its price target to $865, citing robust Dupixent sales, which grew by 12% quarter-over-quarter to $4.86 billion. Cantor Fitzgerald increased its price target to $740, highlighting improved clarity on regulatory timelines for Eylea HD. BofA Securities raised its target to $627, acknowledging broad-based outperformance across Regeneron’s product portfolio. Baird also adjusted its target to $630, noting resilience in the Eylea franchise despite previous market concerns. These developments reflect a positive assessment of Regeneron’s recent financial performance and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.